Treatment of bipolar depression: focus on pharmacologic therapies

References

• Mitchell PB, Malhi GS. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Dis.6, 530–539 (2004).
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schttler PJ, Endicott J, Maser J, Solomon DA. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psych.59, 530–537 (2002).
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schuttler PJ, Coryell W, Endicott J, Maser JD. Prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psych.60, 261–269 (2003).
   PubMed Web of Science ®Google Scholar
• Bauer MS, Kirk GF, Gavin C, Williford WO. Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study. J. Affect. Disorders65, 231–241 (2001).
   PubMed Web of Science ®Google Scholar
• Bryant-Comstock L, Stender M, Devercelli G. Healthcare utilization and costs among privately insured patients with bipolar I disorder. Bipolar Dis.6, 398–405 (2002).
   Google Scholar
• Altshuler LL, Gitlin MJ, Mintz J, Leight KL, Frye MA. Subsyndromal depression is associated with functional impairment in-patients with bipolar disorder. J. Clin. Psychiatry63, 807–811 (2002).
   PubMed Web of Science ®Google Scholar
• Muller-Oelinghausen B, Berghofer A, Bauer M. Bipolar disorder. Lancet359, 241–247 (2002).
   Google Scholar
• Tondo L, Isacsson G, Baldessarini RJ. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs17, 491–511 (2003).
   PubMed Web of Science ®Google Scholar
• Chen Y-W, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other axis I disorders. Biol. Psychiatry39, 896–899 (1996).
   PubMed Web of Science ®Google Scholar
• Mitchell PB, Slade T, Andrews G. Twelve-month prevalence and disability of DSM-IV bipolar disorder in an Australian general population survey. Psychol. Med.34, 777–785 (2004).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Rubinow DR, Holmes C, Abelson JM, Zhao S. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol. Med.27, 1079–1080 (1997).
   PubMed Web of Science ®Google Scholar
• Goodwin F, Jamison K. Manic-Depressive Illness. Oxford University Press, NY, USA, 1–938 (1990).
   Google Scholar
• Harris EC, Barraclough B. Suicide as an outcome for mental disorders. Br. J. Psychiatry170, 205–228 (1997).
   PubMed Web of Science ®Google Scholar
• Dilsaver SC, Chen Y-W, Swann AC, Shoaib AM, Tsai-Dilsaver Y, Krajewski KJ. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psych. Res.73, 47–56 (1997).
   PubMed Web of Science ®Google Scholar
• Isometsa ET, Henriksson MM, Aro HM, Lonnqvist JK. Suicide in bipolar disorder in Finland. Am. J. Psychiatry151, 1020–1024 (1994).
   PubMed Web of Science ®Google Scholar
• Lopez P, Mosquera F, de Leon J et al. Suicide attempts in bipolar patients. J. Clin. Psychiatry62, 963–966 (2001).
   PubMed Web of Science ®Google Scholar
• Rihmer Z, Kiss K. Bipolar disorders and suicide behaviour. Bipolar Dis.4, 21–25 (2002).
   PubMedGoogle Scholar
• Frankle WG, Perlis RH, Deckersbach T et al. Bipolar depression: relationship between episode length and antidepressant treatment. Psychol. Med.32, 1417–1423 (2002).
   PubMed Web of Science ®Google Scholar
• Crown WH, Finklenstein S, Berndt ER et al. The impact of treatment-resistant depression on healthcare utilization and costs. J. Clin. Psychiatry63, 963–971 (2002).
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Konno W, Morinobu S, Harai H, Kitamura T, Takahashi K. Course and outcome of depressive episodes: comparison between bipolar, unipolar and subthreshold depression. Psychiatry Res.96, 211–220 (2000).
   Google Scholar
• Bottlender R, Rudolf D, Jager M, Strauss A, Moller H-J. Are bipolar I depressive patients less responsive to treatment with antidepressants than unipolar depressive patients? Result from a case control study. Eur. Psychiatry17, 200–205 (2002).
   Google Scholar
• Zarate CA, Payne JL, Singh J et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry56, 54–60 (2004).
   PubMed Web of Science ®Google Scholar
• Hadjipavlou G, Mok H, Yatham LN. Pharmacotherapy of bipolar II disorder: a critical review of current evidence. Bipolar Dis.6, 14–25 (2004).
   PubMed Web of Science ®Google Scholar
• Bauer MS, Mitchner L. What is a ‘mood stabiliser’? An evidence-based response. Am. J. Psychiatry161, 13–18 (2004).
   Google Scholar
• Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry161, 1537–1547 (2004).
   PubMed Web of Science ®Google Scholar
• Coryell W, Colomon D, Turvey C et al. The long-term course of rapid-cycling bipolar disorder. Arch. Gen. Psych.60, 914–920 (2003).
   PubMed Web of Science ®Google Scholar
• Malhi GS, Mitchell PB, Salim S. Bipolar depression: management options. CNS Drugs17, 9–25 (2003).
   PubMed Web of Science ®Google Scholar
• Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br. J. Psychiatry164, 549–550 (1994).
   PubMed Web of Science ®Google Scholar
• Bottlender R, Rudolf D, Straub A, Moller H-J. Mood stabilizers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J. Affect. Disorders63, 79–83 (2001).
   PubMed Web of Science ®Google Scholar
• Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M. Antidepressant-induced mania in bipolar patients: identification of risk factors. J. Clin. Psychiatry62, 249–255 (2001).
   PubMed Web of Science ®Google Scholar
• Altshuler L, Suppes T, Black D et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am. J. Psychiatry160, 1252–1262 (2003).
   PubMed Web of Science ®Google Scholar
• Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust. NZ J. Psychiatry38, 280–305 (2004).
   PubMed Web of Science ®Google Scholar
• Suppes T, Baldessarini RJ, Faedda GL et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch. Gen. Psych.48, 1082–1088 (1991).
   PubMed Web of Science ®Google Scholar
• Zornberg GL, Pope Jr. HG. Treatment of depression in bipolar disorder: new directions for research.J. Clin. Psychopharmacol.13, 397–408 (1993).
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Evans DL, Gyulai L et al. Double -blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am. J. Psychiatry158, 906–912 (2001).
   PubMed Web of Science ®Google Scholar
• Daly JJ, Prudic J, Devanand DP et al. ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disorders3, 95–104 (2001).
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Post RM. carbamazepine in manic-depressive illness: a new treatment. Am. J. Psychiatry137, 782–790 (1980).
   PubMed Web of Science ®Google Scholar
• Post RM, Uhde TW, Roy-Byrne P et al. Antidepressant effects of carbamazepine. Am. J. Psychiatry143, 29–34 (1986).
   PubMed Web of Science ®Google Scholar
• Post RM, Leverich GS, Denicoff KD et al. Alternative approaches to refractory depression in bipolar illness. Depression Anxiety5, 73–83 (1997).
   PubMedGoogle Scholar
• Dilsaver SC, Swann SC, Chen Y et al. Treatment of bipolar depression with carbamazepine: results of an open study. Biol. Psychiatry40, 935–937 (1996)
   PubMedGoogle Scholar
• Kramlinger KG, Post RM. The addition of lithium to carbamazepine. Arch. Gen. Psych.46, 794–800 (1989).
   PubMedGoogle Scholar
• Post RM, Ketter TA, Denicoff K et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology128, 115–129 (1996)
   PubMed Web of Science ®Google Scholar
• Young LT, Joffe RT, Robb JC et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am. J. Psychiatry157, 124–126 (2000).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Keck PE Jr. Treatment guidelines for valproate in bipolar, schizoaffective disorders. Can. J. Psychiatry38, 62–66 (1993)
   PubMedGoogle Scholar
• Winsberg ME, DeGolia SG, Strong CM et al. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J. Affect. Disorders67, 207–212 (2001).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psychiatry60, 79–88 (1999).
   PubMed Web of Science ®Google Scholar
• Frye MA, Ketter TA, Kimbrell TA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacol.20, 607–614 (2000).
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs63, 2029–2050 (2003).
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psych.60, 1079–1088 (2003).
   PubMed Web of Science ®Google Scholar
• Macfadden W, Calabrese J. Presented at 24th CINP Meeting, June 20–24, Paris, France (2004).
   Google Scholar
• Mitchell PB, Wilhelm K, Parker G, Austin M-P, Rutgers P, Malhi GS. The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J. Clin. Psychiatry62, 212–216 (2001).
   PubMed Web of Science ®Google Scholar
• Singh J, Zarate CA, Krystal AD. Case report: successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. Psychopharmacology173, 227–228 (2004).
   PubMed Web of Science ®Google Scholar
• Hahn C-G, Gyulai L, Baldassano CF, Lenox RH. The current understanding of lamotrigine as a mood stabilizer. J. Clin. Psychiatry65, 791–804 (2004).
   PubMed Web of Science ®Google Scholar
• Burgess S, Geddes J, Hawton K et al. Lithium for maintenance treatment of mood disorders (Cochrane Review). The Cochrane Library 4 Update Software, Oxford, UK (2001).
   Google Scholar
• Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA27, 918–924 (1994).
   Google Scholar
• Prien RF, Klett CJ, Caffey EM Jr. Lithium carbonate and imipramine in prevention of affective episodes; a comparison in recurrent affective illness. Arch. Gen. Psych.29, 420–425 (1973).
   PubMed Web of Science ®Google Scholar
• Kane JM, Quitkin FM, Rifkin A et al. A. Lithium carbonate and Imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch. Gen. Psych.39, 1065–1069 (1982).
   PubMed Web of Science ®Google Scholar
• Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry161, 217–222 (2004).
   PubMed Web of Science ®Google Scholar
• Macritchie KAN, Geddes JR, Scott J et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Cochrane Review). The Cochrane Library 4 Update Software, Oxford, UK (2001).
   Google Scholar
• Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled12-month trial of divalproex and lithium in treatment of out-patients with bipolar I disorder. Arch. Gen. Psych.57, 481–489 (2000).
   PubMed Web of Science ®Google Scholar
• Dardennes R, Even C, Bange F et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: a meta-analysis. Br. J. Psychiatry166, 378–381 (1995).
   PubMed Web of Science ®Google Scholar
• Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr. Scand.100, 406–417 (1999).
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ. Effects of lithium treatment and its discontinuation on suicidal behaviour in bipolar manic depressive disorders. J. Clin. Psychiatry60, 77–84 (1999).
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA290, 1467–1473 (2002).
   Google Scholar
• Okuma T, Inanaga K, Otsuki S et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology73, 95–95 (1981).
   PubMed Web of Science ®Google Scholar
• Denicoff KD, Smith-Jackson EE, Disney ER et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J. Clin. Psychiatry58, 470–478 (1997).
   PubMed Web of Science ®Google Scholar
• Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium vs. carbamazepine in the maintenance treatment of bipolar disorders – a randomized study. J. Affect. Disorders43, 151–161 (1997).
   PubMed Web of Science ®Google Scholar
• Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology28, 1374–1382 (2003).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psych.60, 392–400 (2003).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs G. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar disorder. J. Clin. Psychiatry64, 1013–1024 (2003).
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J. Clin. Psychiatry65, 432–441 (2004).
   PubMed Web of Science ®Google Scholar
• Tohen M, Ketter TA, Zarate CA et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am. J. Psychiatry160, 1263–1271 (2003)
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs. mood stabiliser alone. Br. J. Psychiatry184, 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Tohen M, Marneros A, Bowden C et al. Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Presented at Stanley Foundation Bipolar Network Meeting, September, Freiberg, Germany (2002).
   Google Scholar
• Lam DH, Watkins ER, Hayward P. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch. Gen. Psych.60, 145–152 (2003).
   PubMed Web of Science ®Google Scholar
• Perry A, Tarrier N, Morriss R et al. Randomized controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. Br. Med. J.318, 149–153 (1999).
   PubMed Web of Science ®Google Scholar
• Miklowitz DJ, George EL, Richards, JA et al. A randomized study of family-focused psychoeducation and pharmacotherapy in the out-patient management of bipolar disorder. Arch. Gen. Psych.60, 904–912 (2003).
   PubMed Web of Science ®Google Scholar
• Colom F, Vieta E, Martinez-Aran A et al. A randomized trial on the efficacy of group psychoeducation prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch. Gen. Psych.60, 402–407 (2003).
   PubMed Web of Science ®Google Scholar
• Frank E, Kupfer DJ, Ihlers CL et al. Interpersonal and social rhythm therapy for bipolar disorder. Behav. Ther.17, 143–149 (1994).
   Google Scholar
• Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: Medication Treatment Of Bipolar Disorder 2000. McGraw-Hill, NY, USA, 1–104 (2000).
   Google Scholar
• Boerlin HL, Gitlin MJ, Zoellner LA et al. Bipolar depression and antidepressant-induced mania: a naturalistic study. J. Clin. Psychiatry59, 374–381 (1998).
   PubMed Web of Science ®Google Scholar
• Bottlender R, Rudolf D, Straub A. Mood-stabilizers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar 1 depressed patients. J. Affect. Disorders63, 79–83 (2001).
   PubMed Web of Science ®Google Scholar
• Vieta E, Martinez-Aran A, Goikolea JM et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry63, 508–512 (2002).
   PubMed Web of Science ®Google Scholar
• UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet361, 799–808 (2003).
   PubMed Web of Science ®Google Scholar
• Vieta E, Colom F. Psychological interventions in bipolar disorder: from wishing thinking to an evidence-based approach. Acta Psych. Scandinav.11(Suppl. 422), 34–38 (2004).
   Google Scholar